Therapy News and Research

RSS

Incivek-combination therapy increases chances of HCV patients achieving viral cure

The drug Incivek, when given in combination with two other medications, can dramatically increase the chances of people chronically infected with untreated genotype 1 hepatitis C virus achieving a viral cure. That's the finding of a study published in the June 23rd issue of the New England Journal of Medicine.

23 Jun 2011

Telaprevir drug shows promise in curing hepatitis C infection

The drug telaprevir (Incivek) provides a dramatic improvement in the treatment of the most common form of hepatitis C infection, says an international team of investigators led by Dr. Ira M. Jacobson of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

23 Jun 2011

High dose statins raise risk of diabetes: Study

According to the latest research taking a high-dose statin to lower cholesterol may increase risk of developing diabetes by as much as 12 percent, but the heart benefits of statins still outweigh the risks.

23 Jun 2011

Molecularly targeted glue for cancer

"This is a totally new approach to cancer therapy," says Professor Patrick Gunning of the Department of Chemical and Physical Sciences. "Everything prior to this has targeted functionally relevant binding sites. Our approach inhibits the mobility of cancer-promoting proteins within cells-essentially, it's like molecularly targeted glue."

23 Jun 2011

BioCision releases three new cryopreservation systems

BioCision, the coolprep company, today announced the release of three new cryopreservation systems: CoolCell FTS30, the first large-capacity, high-density cell freezing system; CoolCell SV2 for freezing cells in larger diameter 2ml vials; and CoolCell 5ml for large cryovial freezing.

22 Jun 2011

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.

22 Jun 2011

Researchers identify natural mechanism linked with Huntington's disease

Johns Hopkins researchers have identified a natural mechanism that might one day be used to block the expression of the mutated gene known to cause Huntington's disease.

22 Jun 2011

22nd Century submits IND to FDA for VLN cigarettes

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.

22 Jun 2011

Strathclyde scientists receive British Heart Foundation grant to study hypertension

Scientists at the University of Strathclyde's Institute of Pharmacy and Biomedical Sciences, have recently been awarded almost -155,000 by the British Heart Foundation to conduct a two year investigation aimed at improving the treatment of hypertension.

22 Jun 2011

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Oxford BioMedica plc, a leading gene therapy company, today announces that the first dose level of RetinoStat is safe and well-tolerated at one month following treatment.

22 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Exercise helps overcome side effects of cancer, improves survival

Brain cancer patients who are able to exercise live significantly longer than sedentary patients, scientists at the Duke Cancer Institute report.

22 Jun 2011

New-onset diabetes risk increases with intensive-dose statin therapy

An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

A yet unidentified component of coffee interacts with the beverage's caffeine, which could be a surprising reason why daily coffee intake protects against Alzheimer's disease.

22 Jun 2011

Government and private sector must work together on HIV vaccine

The success of antiretroviral therapy for HIV/AIDS "has fooled us into believing HIV is under control. It is not. … The fact remains that no sexually acquired infection has ever been controlled in democratic societies except by vaccines," Lawrence Corey, president and director of the Fred Hutchinson Cancer Research Center and principal investigator of the international HIV Vaccine Trials Network, writes in a Wall Street Journal opinion piece.

21 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

Wayne State team receives $330,000 NSF grant to develop 3-D neural probe for tinnitus

A team of Wayne State University researchers was awarded $330,000 from the National Science Foundation (NSF) to develop a 3-D neural probe. Their aim is to develop an implantable device that will suppress tinnitus, a neurological disorder that affects more than 250 million people worldwide.

21 Jun 2011